Skip to content

Deep learning based on multi-regional dynamic contrast-enhanced MRI to predict axillary lymph node response after neoadjuvant chemotherapy for breast cancer

Deep learning based on multi-regional dynamic contrast-enhanced MRI to predict axillary lymph node response after neoadjuvant chemotherapy for breast cancer

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2400081165
Enrollment
Unknown
Registered
2024-02-26
Start date
2024-02-26
Completion date
Unknown
Last updated
2024-03-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast cancer

Interventions

Sponsors

Yantai Yuhuangding Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
25 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1.the patients were confirmed by biopsy as invasive breast cancer with ipsilateral ALN metastases; 2.the patients should have adequate hematologic, liver, and renal function at enrollment; 3. the enrolled patients were planned to receive a standard NAC treatment, followed by ALND; patients who have been undergoing or have completed the standard NAC waiting for the surgery will also deemed eligible; 4.axillary lymph node pathological NAC response (pCR or non-pCR) was confirmed; 5. both MRI and biopsy were conducted within 2 weeks before NAC; 6.no other tumor occurred during NAC and operation.

Exclusion criteria

Exclusion criteria: 1.a history of chemoradiation therapy, surgery, or malignancy; 2.the patients received non-standard treatment or did not complete the NAC regimen; 3.no surgery was performed or the results of postoperative pathology were incomplete; 4.lack of clinical information, MRI images for analysis requirements; 5.insufficient quality of MRI images; 6.patients with multifocal, bilateral, or occult breast cancer.

Design outcomes

Primary

MeasureTime frame
Area under receiver operating characteristic curve;Accuracy;

Secondary

MeasureTime frame
Sensitivity;Specificity;

Countries

China

Contacts

Public ContactNing Mao

Yantai Yuhuangding Hospital

maoning@pku.edu.cn+86 131 0535 1972

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026